359 related articles for article (PubMed ID: 23651400)
1. Nanosuspensions of poorly water soluble drugs prepared by top-down technologies.
Zhang X; Li LC; Mao S
Curr Pharm Des; 2014; 20(3):388-407. PubMed ID: 23651400
[TBL] [Abstract][Full Text] [Related]
2. Nanosuspensions of poorly water-soluble drugs prepared by bottom-up technologies.
Du J; Li X; Zhao H; Zhou Y; Wang L; Tian S; Wang Y
Int J Pharm; 2015 Nov; 495(2):738-49. PubMed ID: 26383838
[TBL] [Abstract][Full Text] [Related]
3. Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery.
Lai F; Schlich M; Pireddu R; Corrias F; Fadda AM; Sinico C
Curr Pharm Des; 2015; 21(42):6089-103. PubMed ID: 26503149
[TBL] [Abstract][Full Text] [Related]
4. Effects of nanosuspension formulations on transport, pharmacokinetics, in vivo targeting and efficacy for poorly water-soluble drugs.
Wang Y; Miao X; Sun L; Song J; Bi C; Yang X; Zheng Y
Curr Pharm Des; 2014; 20(3):454-73. PubMed ID: 23651402
[TBL] [Abstract][Full Text] [Related]
5. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives.
Shegokar R; Müller RH
Int J Pharm; 2010 Oct; 399(1-2):129-39. PubMed ID: 20674732
[TBL] [Abstract][Full Text] [Related]
6. Formulation aspects of intravenous nanosuspensions.
Patel D; Zode SS; Bansal AK
Int J Pharm; 2020 Aug; 586():119555. PubMed ID: 32562654
[TBL] [Abstract][Full Text] [Related]
7. Design of dry nanosuspension with highly spontaneous dispersible characteristics to develop solubilized formulation for poorly water-soluble drugs.
Niwa T; Miura S; Danjo K
Pharm Res; 2011 Sep; 28(9):2339-49. PubMed ID: 21626059
[TBL] [Abstract][Full Text] [Related]
8. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical nanocrystals: production by wet milling and applications.
Malamatari M; Taylor KMG; Malamataris S; Douroumis D; Kachrimanis K
Drug Discov Today; 2018 Mar; 23(3):534-547. PubMed ID: 29326082
[TBL] [Abstract][Full Text] [Related]
10. Supercritical fluid particle design for poorly water-soluble drugs (review).
Sun Y
Curr Pharm Des; 2014; 20(3):349-68. PubMed ID: 23651403
[TBL] [Abstract][Full Text] [Related]
11. Nanosuspensions technology as a master key for nature products drug delivery and In vivo fate.
Ma Y; Cong Z; Gao P; Wang Y
Eur J Pharm Sci; 2023 Jun; 185():106425. PubMed ID: 36934992
[TBL] [Abstract][Full Text] [Related]
12. Effect of drug physico-chemical properties on the efficiency of top-down process and characterization of nanosuspension.
Liu T; Müller RH; Möschwitzer JP
Expert Opin Drug Deliv; 2015; 12(11):1741-54. PubMed ID: 26098043
[TBL] [Abstract][Full Text] [Related]
13. Nano-sized crystalline drug production by milling technology.
Moribe K; Ueda K; Limwikrant W; Higashi K; Yamamoto K
Curr Pharm Des; 2013; 19(35):6246-58. PubMed ID: 23470002
[TBL] [Abstract][Full Text] [Related]
14. Nanosuspensions: a promising drug delivery strategy.
Patravale VB; Date AA; Kulkarni RM
J Pharm Pharmacol; 2004 Jul; 56(7):827-40. PubMed ID: 15233860
[TBL] [Abstract][Full Text] [Related]
15. Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.
Leone F; Cavalli R
Expert Opin Drug Deliv; 2015; 12(10):1607-25. PubMed ID: 25960000
[TBL] [Abstract][Full Text] [Related]
16. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
[TBL] [Abstract][Full Text] [Related]
17. Drug nanocrystals in the commercial pharmaceutical development process.
Möschwitzer JP
Int J Pharm; 2013 Aug; 453(1):142-56. PubMed ID: 23000841
[TBL] [Abstract][Full Text] [Related]
18. Spray drying of API nanosuspensions: Importance of drying temperature, type and content of matrix former and particle size for successful formulation and process development.
Czyz S; Wewers M; Finke JH; Kwade A; van Eerdenbrugh B; Juhnke M; Bunjes H
Eur J Pharm Biopharm; 2020 Jul; 152():63-71. PubMed ID: 32376369
[TBL] [Abstract][Full Text] [Related]
19. Nanosuspensions in drug delivery: recent advances, patent scenarios, and commercialization aspects.
Chavhan SS; Petkar KC; Sawant KK
Crit Rev Ther Drug Carrier Syst; 2011; 28(5):447-88. PubMed ID: 22077201
[TBL] [Abstract][Full Text] [Related]
20. Solution calorimetry as an alternative approach for dissolution testing of nanosuspensions.
Kayaert P; Li B; Jimidar I; Rombaut P; Ahssini F; Van den Mooter G
Eur J Pharm Biopharm; 2010 Nov; 76(3):507-13. PubMed ID: 20887787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
